Cemiplimab for advanced skin cancer after kidney transplant
Treatments studied
Part of Cancer, Immune system & allergy, Kidney & urinary, Skin clinical trials.
This trial tests whether the immunotherapy drug cemiplimab can treat advanced squamous cell skin cancer in people who have had a kidney transplant. It aims to see if the drug can shrink tumors while keeping the transplanted kidney working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or spread squamous cell skin cancer that cannot be removed by surgery or has come back after treatment.
- You have had a kidney transplant at least 6 months ago, your kidney is working well (GFR at least 30), and you have not had a recent rejection needing treatment.
- You are not taking certain anti-rejection drugs called antiproliferatives, or you can stop them for 7 days before starting the study drug.
- You can switch to a specific anti-rejection drug combination (sirolimus and prednisone) if you are not already on it.
- You have not had certain immunotherapies or other checkpoint inhibitor drugs before.
- You are willing to use highly effective birth control during the study and for 4 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This trial is testing whether a new blood test can predict how well the drug cemiplimab works for skin cancer and if it causes side effects. It may help doctors better match treatments to patients.
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This study tests a new immunotherapy drug (cemiplimab), either alone or combined with another drug (fianlimab), after targeted radiation (SBRT) to kill cancer cells. It is for people with advanced clear cell kidney cancer who have few spots of spread and have not had many prior treatments.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.